Slide 1: Understanding the Benefits of Neuronetics' Greenbrook Acquisition
Exhibit 99.1 Understanding the Benefits of Neuronetics’ Greenbrook Acquisition October 2, 2024
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (“Neuronetics” or the “Company”) relating to market size and growth and other data about the industry in which the Company operates. These estimates and
Slide 3: Forward Looking Statements (continued)
Forward Looking Statements (continued) • the combined company’s success in retaining or recruiting, or changes required in, its officers, key employees or directors; • the combined company’s ability to achieve the expected benefits from the Arrangement within the expected time frames or at all; • th
Slide 4: No Offer or Solicitation
No Offer or Solicitation This communication is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities,
Slide 5: Non-GAAP Financial Measures
Non-GAAP Financial Measures In addition to financial measures prepared in accordance with accounting principles generally accepted in the United States (“GAAP”), from time to time we may use or publicly disclose certain non-GAAP financial measures in the course of our financial presentations, earnin
Slide 6: Neuronetics + Greenbrook TMS
Neuronetics + Greenbrook TMS Combining two of the nation’s largest mental health companies to create an organization with the ability to leverage its scale and capabilities to treat more patients suffering from mental health conditions 6
Slide 7: Significant, Underpenetrated U.S. TMS Market Opportunity
Significant, Underpenetrated U.S. TMS Market Opportunity U.S. Adults and Adolescents Patients suffering from depression, >29 million 1 depression with anxiety, and OCD Patients currently 2,3 10.9 million being treated Poorly served by 4,5,6 4.4 million medication Patients treated ~100 0.4% thousand
Slide 8: Transaction Overview
Transaction Overview • All of Greenbrook TMS’ outstanding long-term debt will be converted into common shares of Greenbrook (“Greenbrook Shares”) prior to closing of the proposed Arrangement • All-stock transaction with pro forma ownership: 57% Neuronetics, 43% Greenbrook TMS Structure • Each Greenb
Slide 9: Neuronetics and Greenbrook TMS Overview
Neuronetics and Greenbrook TMS Overview Neuronetics Greenbrook TMS Neuronetics’ NeuroStar Advanced Therapy for Mental Health is the leading Greenbrook is a leading provider of TMS therapy in the U.S. for the treatment transcranial magnetic stimulation (“TMS”) treatment for major depressive of mental
Slide 10: Transaction Rationale
Transaction Rationale Creates a vertically integrated organization providing access to mental health treatment with significant scale in the U.S. Strategic Financial • Increased brand awareness for NeuroStar • Increased revenue scale and strong growth trajectory • More consistent delivery of best pr
Slide 11: Key Reasons to Support Neuronetics' Acquisition of Greenbrook
Key Reasons to Support Neuronetics’ Acquisition of Greenbrook • Expanded Revenue Opportunities from a Broader Portfolio of Mental Health- Related Products and Services • Creates Benefits for All of Neuronetics’ Customers • Ability to Leverage the Better Me Platform to Better Operationalize Greenbroo
Slide 12: Expanded Revenue Opportunities from a Broader Portfolio of Products and Services
Expanded Revenue Opportunities from a Broader Portfolio of Mental Health-Related Products and Services • Strength of the combined company allows for investment in clinic product diversification with short ramp-up times and attractive return profiles • Stronger combined balance sheet offers additiona
Slide 13: Creates Benefits for All of Neuronetics' Customers
Creates Benefits for All of Neuronetics’ Customers • Increases brand recognition for NeuroStar to educate more patients • Expands training opportunities on how to incorporate med management, Spravato, and NeuroStar into practices • Potential to improve customer business operations through: – Access
Slide 14: Ability to Leverage the Better Me Platform to Operationalize Greenbrook Clinics
Ability to Leverage the Better Me Platform to Better Operationalize Greenbrook Clinics • Direct control of Greenbrook clinic adoption of Better Me Program standards to better educate patients and increasing utilization – Consistent patient intake – Consistent patient education – Consistent patient e
Slide 15: Optimizes Marketing Strategies and Spending
Optimizes Marketing Strategies and Spending to Improve the Patient Experience and Return on Investment • Leverage the Better Me Provider platform to better operationalize Greenbrook clinics by providing consistent patient intake, education, and overall experience – Better Me Provider accounts, inclu
Slide 16: Attractive Financial Profile and Stronger Balance Sheet
Attractive Financial Profile and Stronger Balance Sheet • Combination effectively doubles the revenue of the business • Material identified cost savings expected to be realized in 2025 and thereafter • Accelerated path to Adjusted EBITDA and cash flow positive compared to Neuronetics standalone • Me
Slide 17: Attractive Financial Profile
Attractive Financial Profile • Increased revenue scale and strong growth profile • $15 million of annual cost savings identified • Accelerated path to profitability and expect to be Adjusted EBITDA and cash flow positive for the full fiscal year 2025, excluding one- time costs related to the transac
Slide 18: Stronger Balance Sheet
Stronger Balance Sheet • 100% of Greenbrook’s LT debt of Debt to Revenue & Net Debt to Revenue Ratio ~$150 million being converted into (1) (2) Standalone Neuronetics Estimated Combined Greenbrook Shares or eliminated 65% prior to / at closing 56% • Enhanced pro forma liquidity from 49% Neuronetics
Slide 19: References
References 1. NIMH https://www.nimh.nih.gov/health/statistics/major-depression.shtml, accessed 4/29/2024 2. Depression- Pharma Intelligence Disease Analysis, www.datamonitorhealthcare.com, Publication Date: June 2021 3. OCD- Pharma Intelligence Disease Analysis, www.datamonitorhealthcare.com, Public
Slide 20: Appendix
Appendix
Slide 21: Non-GAAP Financial Measures Reconciliation
Non-GAAP Financial Measures Reconciliation The following tables present our calculation of Adjusted EBITDA and reconciliation of Adjusted EBITDA to the GAAP financial measure of net income (loss) Standalone Neuronetics Reconciliation (US$ in millions) For the Year Ending, For the Year Ending Decembe
Slide 22: NeuroStar
_/ NeuroStar¢